Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AssigneeVivus, Inc.
InventorsLeland F. Wilson, Paul C. Doherty, Jr., Virgil A. Place, William L. Smith, Ibrahim AbouBakr Abdel-Hamid Abdou Ali
Life of this patent
Estimating the term…
Abstract
A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as “as needed” basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.
Claims94
A method for treating premature ejaculation, which comprises administering to a male individual in need of such treatment a therapeutically effective amount of an active agent selected from the group consisting of phosphodiesterase inhibitors and pharmaceutically acceptable salts, esters, amides, prodrugs, and active metabolites thereof.
A pharmaceutical formulation for treating premature ejaculation and adapted for transmucosal drug administration, comprising a therapeutically effective amount of a phosphodiesterase inhibitor and a carrier suitable for transmucosal drug delivery buccally, sublingually, intranasally, rectally, or by inhalation.
A packaged kit for a patient to use in the treatment of premature ejaculation, comprising:
- a pharmaceutical formulation of a phosphodiesterase inhibitor;
- a container housing the pharmaceutical formulation during storage and prior to administration;
- and instructions for carrying out drug administration in a manner effective to treat premature ejaculation.
Dependencies are inferred from the claim text.